Featured news from NHIVNA
HIV-related news from NAM
EASL issues new hepatitis C treatment recommendations for all genotypes
Liz Highleyman, 2016-09-26 10:40:00
The European Association for
the Study of the Liver (EASL) released its latest recommendations on treatment
of hepatitis C at a special meeting last Thursday in Paris. The
updated guidelines now include highly effective interferon-free options for all
hepatitis C virus (HCV) genotypes and for the most challenging patients.
EASL usually releases revised recommendations at
its International Liver Congress in the spring, but this year the guidelines panel decided to hold off the release to wait for European
approval of two newer direct-acting antiviral regimens, grazoprevir/elbasvir (Zepatier) and sofosbuvir/velpatasvir (Epclusa). The recommendations were
presented at an evening session preceding a special meeting, New Perspectives in Hepatitis C Virus Infection - The
Roadmap for Cure
coordinator Jean-Michel Pawlotsky presented a summary of the recommendations,
followed by a discussion with panel members Alessio Aghemo, David Back,
Geoffrey Dusheiko, Xavier Forns and Massimo Puoti, along with EASL Secretary
General Laurent Castera and Francesco Negro of the EASL governing board; member Christoph
Sarrazin was absent.
The guidelines - now in press in the Journal of Hepatology and available on the EASL website - are designed to be
flexible enough to be relevant in countries with different approval mechanisms
and funding systems.
is committed to making recommendations that every country can use," Prof
Pawlotsky said. "We hope these guidelines can help people all over the